These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25822147)

  • 1. Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.
    Sun Y; Florer J; Mayhew CN; Jia Z; Zhao Z; Xu K; Ran H; Liou B; Zhang W; Setchell KD; Gu J; Grabowski GA
    PLoS One; 2015; 10(3):e0118771. PubMed ID: 25822147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease.
    Aflaki E; Stubblefield BK; McGlinchey RP; McMahon B; Ory DS; Sidransky E
    Neurobiol Dis; 2020 Feb; 134():104647. PubMed ID: 31669751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.
    Peng Y; Liou B; Inskeep V; Blackwood R; Mayhew CN; Grabowski GA; Sun Y
    Hum Mol Genet; 2019 Oct; 28(20):3406-3421. PubMed ID: 31373366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.
    Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA
    Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.
    Srikanth MP; Jones JW; Kane M; Awad O; Park TS; Zambidis ET; Feldman RA
    Stem Cells Transl Med; 2021 Jul; 10(7):1081-1094. PubMed ID: 33656802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
    Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
    Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.
    Farfel-Becker T; Vitner EB; Kelly SL; Bame JR; Duan J; Shinder V; Merrill AH; Dobrenis K; Futerman AH
    Hum Mol Genet; 2014 Feb; 23(4):843-54. PubMed ID: 24064337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity.
    Sasagasako N; Kobayashi T; Yamaguchi Y; Shinnoh N; Goto I
    J Biochem; 1994 Jan; 115(1):113-9. PubMed ID: 8188616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.
    Aflaki E; Stubblefield BK; Maniwang E; Lopez G; Moaven N; Goldin E; Marugan J; Patnaik S; Dutra A; Southall N; Zheng W; Tayebi N; Sidransky E
    Sci Transl Med; 2014 Jun; 6(240):240ra73. PubMed ID: 24920659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
    Xu YH; Sun Y; Ran H; Quinn B; Witte D; Grabowski GA
    Mol Genet Metab; 2011 Apr; 102(4):436-47. PubMed ID: 21257328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease.
    Srikanth MP; Feldman RA
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cellular cobalamin metabolism in Gaucher disease.
    Basgalupp SP; Siebert M; Ferreira C; Behringer S; Spiekerkoetter U; Hannibal L; Schwartz IVD
    BMC Med Genet; 2020 Jan; 21(1):12. PubMed ID: 31931749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.
    Xu YH; Xu K; Sun Y; Liou B; Quinn B; Li RH; Xue L; Zhang W; Setchell KD; Witte D; Grabowski GA
    Hum Mol Genet; 2014 Aug; 23(15):3943-57. PubMed ID: 24599400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
    Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
    J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
    Sun Y; Zhang W; Xu YH; Quinn B; Dasgupta N; Liou B; Setchell KD; Grabowski GA
    PLoS One; 2013; 8(3):e57560. PubMed ID: 23520473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells.
    Awad O; Sarkar C; Panicker LM; Miller D; Zeng X; Sgambato JA; Lipinski MM; Feldman RA
    Hum Mol Genet; 2015 Oct; 24(20):5775-88. PubMed ID: 26220978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cell line (INSAi001-A) from a Gaucher disease type 3 patient compound heterozygote for mutations in the GBA1 gene.
    Duarte AJ; Ribeiro D; Santos R; Moreira L; Bragança J; Amaral O
    Stem Cell Res; 2019 Dec; 41():101595. PubMed ID: 31678773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.